2. Search Result
Search Result
Results for "

CDK12/13

" in MedChemExpress (MCE) Product Catalog:
Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-151110
    PROTAC CDK12/13 Degrader-1

    		PROTACs CDK Cancer
    PROTAC CDK12/13 Degrader-1 (7f) is a highly selective cell cycle protein-dependent kinase CDK12/CDK13 dual degrader with the DC50 values of 2.2 nM and 2.1 nM, respectively. PROTAC CDK12/13 Degrader-1 has anti-proliferative activity and can be used in breast cancer research .
    PROTAC CDK12/13 Degrader-1
  • HY-151110A
    PROTAC CDK12/13 Degrader-1 TFA

    		PROTACs CDK Cancer
    PROTAC CDK12/13 Degrader-1 (7f) TFA is a highly selective cell cycle protein-dependent kinase CDK12/CDK13 dual degrader with the DC50 values of 2.2 nM and 2.1 nM, respectively. PROTAC CDK12/13 Degrader-1 TFA has anti-proliferative activity and can be used in breast cancer research .
    PROTAC CDK12/13 Degrader-1 TFA
  • HY-145072
    BSJ-01-175

    		CDK Cancer
    BSJ-01-175 is a potent and selective CDK12/13 covalent inhibitor. BSJ-01-175 demonstrates exquisite selectivity, potent inhibition of RNA polymerase II phosphorylation, and downregulation of CDK12-targeted genes in cancer cells .
    BSJ-01-175
  • HY-168658
    CDK12/13 ligand 2

    		Ligands for Target Protein for PROTAC Cancer
    CDK12/13 ligand 2 is a potent CDK12 and CDK13 ligand. CDK12/13 ligand 2 can be used to synthesize YJ1206 (HY-168555) .
    CDK12/13 ligand 2
  • HY-160284
    CDK12/13-IN-1

    		CDK Cancer
    CDK12/13-IN-1 (Compound 4) is a CDK12/13 inhibitor. CDK12/13-IN-1 has antitumor activity .
    CDK12/13-IN-1
  • HY-173042
    CDK12/13-IN-2

    		CDK Cancer
    CDK12/13-IN-2 (Compound 24) is a covalent inhibitor of CDK12/13, with IC50 values of 15.5 nM and 12.2 nM for CDK12 and CDK13, respectively. CDK12/13-IN-2 can inhibit the proliferation of breast cancer cells and can be used in the research of triple-negative breast cancer .
    CDK12/13-IN-2
  • HY-173059
    CDK12/13-IN-3

    		CDK Cancer
    CDK12/13-IN-3 (Compound 12b) is the orally active inhibitor for CDK that inhibits CDK12 and CDK13 with IC50 of 107.4 nM and 79.4 nM. CDK12/13-IN-3 inhibits the phosphorylation of Ser2 on the CTD of RNA polymerase II, induces DNA damage, and downregulates the gene expression of DNA damage response (DDR). CDK12/13-IN-3 exhibits antiproliferative activity against multiple cancer cells with IC50 of nanomolar levels. CDK12/13-IN-3 exhibits antitumor effect in mouse models, exhibits good pharmacokinetic properties with an oral bioavailability of 53.6% .
    CDK12/13-IN-3
  • HY-168163
    CDK12/13 ligand 1

    		CDK Cancer
    ALK-IN-29 (compound 4c) has a certain inhibitory effect on tyrosine protein kinases ALK, CDK2/CyclinE1 and FAK, among which the strongest inhibitory effect on ALK kinase is 40.63% at a concentration of 10 μM. ALK-IN-29 can be used for anti-cancer research .
    CDK12/13 ligand 1
  • HY-168162
    ZLC491

    		PROTACs CDK Cancer
    ZLC491 is an orally active CDK12/13 PROTAC degrader. ZLC491 can be used in anticancer research .
    ZLC491
  • HY-168197
    Thalidomide-F-piperidine-piperazine-Cbz

    		PROTACs Cancer
    Thalidomide-F-piperidine-piperazine-Cbz Conjugate 110 is a conjugate of E3 ligase and linker for the synthesis of CDK12/13 PROTAC degrader (HY-168162) .
    Thalidomide-F-piperidine-piperazine-Cbz
  • HY-173273
    YJZ5118

    		CDK Cancer
    YJZ5118 is a CDK12/13 inhibitor with IC50 values of 39.5 nM and 26.4 nM against CDK12 and CDK13, respectively. By inducing DNA damage and Apoptosis, YJZ5118 effectively suppresses tumor cell proliferation and exhibits synergistic effects with Akt inhibitors. YJZ5118 can be used for research in the field of cancer .
    YJZ5118
  • HY-153244
    MFH290

    		CDK Cancer
    MFH290 is a potent and highly selective cyclin-dependent kinase 12/13 (CDK12/13) covalent inhibitor. MFH290 forms a covalent bond with Cys-1039 of CDK12 and exhibits excellent kinome selectivity and inhibits the phosphorylation of serine-2 in the C-terminal domain (CTD) of RNA-polymerase II (Pol II). MFH290 is used for cancer research .
    MFH290
  • HY-168556
    YJ9069

    		CDK PROTACs DNA/RNA Synthesis Cancer
    YJ9069 is a selective CDK12/CDK13 PROTAC degrader with an IC50 of 22.22 nM for in VCaP cells. CDK12/13 degradation rapidly triggers gene-length-dependent transcriptional elongation defects, leading to DNA damage and cell-cycle arrest. YJ9069 effectively inhibits proliferation in subsets of prostate cancer cells and significantly suppresses prostate tumor growth. (Pink: CDK12/CDK13 degradation agent (HY-168658); Black: Linker (HY-W015967); Blue: ligand for E3 ligase (HY-103596)) .
    YJ9069

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: